Načítá se...
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
PURPOSE OF REVIEW: Although hypomethylating agents (HMAs) significantly improve outcomes in myelodysplastic syndromes (MDS), only half the patients achieve objective responses, and most responders lose response within 1–2 years. Azacitidine prolongs survival by a median of only 9.5 months. Failure o...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4124617/ https://ncbi.nlm.nih.gov/pubmed/24335709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOH.0000000000000016 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|